AbbVie Presents Long-Term Data On Efficacy And Safety Profile Of RINVOQ (Upadacitinib) In Adults And Adolescents With Moderate To Severe Atopic Dermatitis
AbbVie Presents Long-Term Data On Efficacy And Safety Profile Of RINVOQ (Upadacitinib) In Adults And Adolescents With Moderate To Severe Atopic Dermatitis
艾伯維公佈了RINVOQ（Upadacitinib）在患有中度至重度特應性皮炎的成人和青少年中的療效和安全性的長期數據
AbbVie Presents Long-Term Data On Efficacy And Safety Profile Of RINVOQ (Upadacitinib) In Adults And Adolescents With Moderate To Severe Atopic Dermatitis
AbbVie提供有關RINVOQ(Upadacitinib)在成人和青少年中重度特應性皮膚炎的有效性和安全性的長期數據
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。